Novo Nordisk was down 2.87% and Eli Lilly 0.95% when the final bell sounded on Wednesday 3 July 2024. US markets were closed on Thursday for the Fourth of July bank holiday. Media reports indicated that researchers from a Harvard-affiliated hospital spearheaded the study and found that patients who used medicines containing GLP-1 and GIP…
Read more
Some prominent therapeutics were featured in the 2023-approval batch. These included Zepbound, an obesity treatment developed by Eli Lilly and Company (LLY), and Leqembi, an Alzheimer's drug from Eisai (ESAYI) and Biogen Inc. (BIIB). On top of the 55 novel drug green lights, the FDA also put its stamp of approval on five gene therapies.…
Read more
On Sunday, 17th December, industry experts noted that while the firm has grown rapidly in 2023, keeping momentum throughout 2024 will be noticeably harder, with investors predicting only a 9% upside on average for next year. Portfolio manager at Antipodes Partners, Nick Cameron, noted 2024 investor predictions: [Novo is] an excellent R&D company, and they’re…
Read more